NASDAQ:CVAC CureVac (CVAC) Stock Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free CVAC Stock Alerts $2.51 -0.09 (-3.46%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$2.34▼$2.5950-Day Range$2.44▼$3.5852-Week Range$2.34▼$12.36Volume1.08 million shsAverage Volume810,926 shsMarket Capitalization$561.94 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get CureVac alerts: Email Address CureVac MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside497.6% Upside$15.00 Price TargetShort InterestBearish5.47% of Float Sold ShortDividend StrengthN/ASustainability-1.88Upright™ Environmental ScoreNews Sentiment0.07Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.97) to ($0.63) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.40 out of 5 starsMedical Sector308th out of 909 stocksPharmaceutical Preparations Industry137th out of 423 stocks 3.0 Analyst's Opinion Consensus RatingCureVac has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageCureVac has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.47% of the float of CureVac has been sold short.Short Interest Ratio / Days to CoverCureVac has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in CureVac has recently increased by 3.09%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCureVac does not currently pay a dividend.Dividend GrowthCureVac does not have a long track record of dividend growth. Previous Next 4.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCureVac has received a 80.57% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "mRNA vaccines" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for CureVac is -1.88. Previous Next 2.3 News and Social Media Coverage News SentimentCureVac has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for CureVac this week, compared to 2 articles on an average week.MarketBeat Follows4 people have added CureVac to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CureVac insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 17.26% of the stock of CureVac is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for CureVac are expected to grow in the coming year, from ($0.97) to ($0.63) per share.Price to Book Value per Share RatioCureVac has a P/B Ratio of 0.87. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsWill this $2 AI stock double overnight?It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!Click here to learn more >>> About CureVac Stock (NASDAQ:CVAC)CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer therapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.Read More CVAC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CVAC Stock News HeadlinesApril 24, 2024 | markets.businessinsider.comEQS-News: CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business UpdateApril 24, 2024 | seekingalpha.comCureVac reports Q4 resultsApril 24, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.April 24, 2024 | finanznachrichten.deCureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza ; Development in Collaboration with GSKApril 24, 2024 | msn.comCureVac BV reports Q4 resultsApril 24, 2024 | markets.businessinsider.comEQS-News: CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSKApril 23, 2024 | finance.yahoo.comCureVac N.V. (NASDAQ:CVAC) stock most popular amongst private equity firms who own 31%, while individual investors hold 30%April 18, 2024 | markets.businessinsider.comCureVac (CVAC) Gets a Buy from Leerink PartnersApril 24, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.April 18, 2024 | americanbankingnews.comCureVac (NASDAQ:CVAC) Hits New 52-Week Low at $2.54April 17, 2024 | markets.businessinsider.comEQS-News: CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer VaccinesApril 16, 2024 | seekingalpha.comCureVac, MD Anderson team up for cancer vaccinesApril 16, 2024 | msn.comCureVac, MD Anderson teams up for cancer vaccinesApril 4, 2024 | msn.comCureVac, GSK Partner Release Data On Influenza Vaccine StudyApril 4, 2024 | markets.businessinsider.comEQS-News: CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSKMarch 25, 2024 | finance.yahoo.comCureVac N.V.: CureVac Provides Risk-Tolerant Investors With Pure-Play Exposure to mRNA CandidatesMarch 16, 2024 | finance.yahoo.comCVAC Oct 2024 7.500 callMarch 8, 2024 | seekingalpha.comCureVac: No Momentum In SightFebruary 1, 2024 | msn.comJimmy Kimmel Gives Trump A Brutal Reality Check On Just How Unpopular He IsFebruary 1, 2024 | finance.yahoo.comHere's Why We're Watching CureVac's (NASDAQ:CVAC) Cash Burn SituationJanuary 26, 2024 | finance.yahoo.comDown -14.25% in 4 Weeks, Here's Why You Should You Buy the Dip in CureVac N.V. (CVAC)January 25, 2024 | finance.yahoo.comDown -15.09% in 4 Weeks, Here's Why You Should You Buy the Dip in CureVac N.V. (CVAC)January 6, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Fusion Pharmaceuticals (FUSN), CureVac (CVAC) and Immunocore Holdings (IMCR)January 5, 2024 | msn.comWhy Biopharmaceutical Player CureVac Shares Are Rising TodayJanuary 5, 2024 | markets.businessinsider.comCureVac Announces Positive Phase 2 Results For COVID-19 Vaccine CandidatesDecember 22, 2023 | finance.yahoo.comThese Analysts Just Made A Huge Downgrade To Their CureVac N.V. (NASDAQ:CVAC) EPS ForecastsDecember 20, 2023 | realmoney.thestreet.comCureVac price target lowered to $6.40 from $8 at BofASee More Headlines Receive CVAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CureVac and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/29/2020Today4/24/2024Next Earnings (Estimated)6/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CVAC CUSIPN/A CIK1809122 Webwww.curevac.com Phone49-70-71988-30Fax49-7071-9883Employees1,049Year FoundedN/APrice Target and Rating Average Stock Price Target$15.00 High Stock Price Target$24.00 Low Stock Price Target$8.00 Potential Upside/Downside+517.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.06 Current Ratio3.56 Quick Ratio3.41 Sales & Book Value Annual Sales$72.33 million Price / Sales7.52 Cash FlowN/A Price / Cash FlowN/A Book Value$2.88 per share Price / Book0.84Miscellaneous Outstanding Shares223,880,000Free FloatN/AMarket Cap$544.03 million OptionableOptionable Beta2.51 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Pierre Kemula B.Sc. (Age 49)MD, CFO & Member of Management Board Comp: $594.58kDr. Malte Greune Ph.D. (Age 59)COO, Member of Management Board & MD Comp: $462.41kDr. Ulrike Gnad-Vogt M.D. (Age 51)Ph.D., Senior VP & Area Head of Oncology Comp: $379.65kDr. Alexander Zehnder M.B.A. (Age 54)M.D., CEO, MD & Member of Management Board Dr. Myriam Mendila M.D. (Age 58)Chief Development Officer, MD & Member of the Management Board Dr. Sarah FakihVice President Corporate Communications & Investor RelationsMr. Marco Rau L.L.M.Ph.D., General CounselMr. Thorsten SchullerHead of Corporate CommunicationsSlavica Stevanovic-HeckHead of Human ResourcesDr. Patrick BaumhofSenior Vice President of TechnologyMore ExecutivesKey CompetitorsNuvation BioNYSE:NUVBGH ResearchNASDAQ:GHRSVerve TherapeuticsNASDAQ:VERVORIC PharmaceuticalsNASDAQ:ORICMineralys TherapeuticsNASDAQ:MLYSView All CompetitorsInstitutional OwnershipBallentine Partners LLCBought 12,597 shares on 4/11/2024Ownership: 0.006%Platinum Investment Management Ltd.Bought 134,626 shares on 2/14/2024Ownership: 0.222%Aristides Capital LLCBought 23,777 shares on 2/13/2024Ownership: 0.011%Dynamic Technology Lab Private LtdBought 37,931 shares on 2/9/2024Ownership: 0.017%Mitsubishi UFJ Asset Management Co. Ltd.Bought 13,687 shares on 2/8/2024Ownership: 0.020%View All Institutional Transactions CVAC Stock Analysis - Frequently Asked Questions Should I buy or sell CureVac stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CureVac in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CVAC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CVAC, but not buy additional shares or sell existing shares. View CVAC analyst ratings or view top-rated stocks. What is CureVac's stock price target for 2024? 3 equities research analysts have issued twelve-month price objectives for CureVac's shares. Their CVAC share price targets range from $8.00 to $24.00. On average, they anticipate the company's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 497.6% from the stock's current price. View analysts price targets for CVAC or view top-rated stocks among Wall Street analysts. How have CVAC shares performed in 2024? CureVac's stock was trading at $4.21 at the beginning of the year. Since then, CVAC stock has decreased by 40.4% and is now trading at $2.51. View the best growth stocks for 2024 here. When is CureVac's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 4th 2024. View our CVAC earnings forecast. How were CureVac's earnings last quarter? CureVac (NASDAQ:CVAC) issued its quarterly earnings data on Sunday, November, 29th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($54.37) by $54.13. What ETFs hold CureVac's stock? ETFs with the largest weight of CureVac (NASDAQ:CVAC) stock in their portfolio include Morningstar US Small Growth (MSGR).Amplify Treatments, Testing and Advancements ETF (GERM). What other stocks do shareholders of CureVac own? Based on aggregate information from My MarketBeat watchlists, some companies that other CureVac investors own include Moderna (MRNA), Tesla (TSLA), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Pfizer (PFE), Johnson & Johnson (JNJ), Zoom Video Communications (ZM) and NIO (NIO). When did CureVac IPO? CureVac (CVAC) raised $200 million in an initial public offering on Friday, August 14th 2020. The company issued 13,300,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and Credit Suisse served as the underwriters for the IPO and Berenberg and Kempen were co-managers. Who are CureVac's major shareholders? CureVac's stock is owned by many different institutional and retail investors. Top institutional investors include Ballentine Partners LLC (0.01%). How do I buy shares of CureVac? Shares of CVAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CVAC) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CureVac Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
